Ribupatide
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity
Fujian Shengdi Pharmaceutical Co · Phase 3 · Recruiting · Enrollment 140
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Group 1: HRS9531 | n/r | n/r | n/r | n/r | n/r |
| Group 2: HRS9531placebo | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.